ALK-Abelló A/S

PINK:AKBLF USA Biotechnology
Market Cap
$4.01 Billion
Market Cap Rank
#4276 Global
#2695 in USA
Share Price
$19.90
Change (1 day)
+0.00%
52-Week Range
$19.90 - $21.35
All Time High
$512.00
About

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more

ALK-Abelló A/S (AKBLF) - Total Liabilities

Latest total liabilities as of September 2025: $2.30 Billion USD

Based on the latest financial reports, ALK-Abelló A/S (AKBLF) has total liabilities worth $2.30 Billion USD as of September 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

ALK-Abelló A/S - Total Liabilities Trend (2005–2024)

This chart illustrates how ALK-Abelló A/S's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

ALK-Abelló A/S Competitors by Total Liabilities

The table below lists competitors of ALK-Abelló A/S ranked by their total liabilities.

Liability Composition Analysis (2005–2024)

This chart breaks down ALK-Abelló A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.56 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.37 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ALK-Abelló A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ALK-Abelló A/S (2005–2024)

The table below shows the annual total liabilities of ALK-Abelló A/S from 2005 to 2024.

Year Total Liabilities Change
2024-12-31 $2.87 Billion +26.06%
2023-12-31 $2.28 Billion -1.77%
2022-12-31 $2.32 Billion -1.28%
2021-12-31 $2.35 Billion -2.49%
2020-12-31 $2.41 Billion +3.92%
2019-12-31 $2.32 Billion +37.54%
2018-12-31 $1.69 Billion +1.08%
2017-12-31 $1.67 Billion -13.31%
2016-12-31 $1.92 Billion +23.73%
2015-12-31 $1.55 Billion +46.01%
2014-12-31 $1.06 Billion +4.51%
2013-12-31 $1.02 Billion +2.10%
2012-12-31 $998.00 Million -15.92%
2011-12-31 $1.19 Billion +46.18%
2010-12-31 $812.00 Million +12.00%
2009-12-31 $725.00 Million +7.25%
2008-12-31 $676.00 Million -4.65%
2007-12-31 $709.00 Million +2.01%
2006-12-31 $695.00 Million -1.70%
2005-12-31 $707.00 Million --